The presence of del(17p) and/or TP53 mutations are parameters of the CLL-International Prognostic Index (CLL-IPI), which combines five parameters (age, clinical stage, TP53, IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. The gene discussed is HLA-G; the disease is B-cell chronic lymphocytic leukemia.